Pregnant Technologist and the I-131 Therapy Patient

Considerations:

• The declared pregnancy triggers a special dose limit for the embryo/fetus (typically 0.5 mSv over the remainder of gestation in most regulatory frameworks) - a limit far below the adult occupational limit.
• I-131 is a high-energy beta emitter with a 364 keV gamma; lead aprons offer little protection against I-131 gamma and provide essentially no protection against the beta once the source is internalized. The 'extra apron' reasoning is not protective.
• The main fetal risk here is internal contamination (volatile liquid I-131, aerosols during draw-up, spills) and prolonged proximity during administration. A declared pregnancy means the employer must adjust duties so the fetal dose stays as low as reasonably achievable and within the special limit.
• A fetal badge program is absent, so you cannot verify dose - this argues for avoiding rather than monitoring exposure.

Immediate action: Do not let her draw up or administer the therapy dose. Reassign the therapy to a qualified colleague (call in a second competent technologist or reschedule the therapy if none is available). She may continue low-exposure duties (e.g., paperwork, non-radioactive QC) pending a formal risk assessment with occupational health and the RSO. Document the disclosure and the reassignment, and arrange a fetal dose assessment/monitoring program before she returns to any radiopharmaceutical handling.

Restructure the workflow:

1. Reassign all I-131 handling - draw-up, administration, and post-administration patient contact - to a non-pregnant, therapy-competent staff member. The pregnant technologist performs no tasks within the therapy room or its immediate controlled area.
2. Route her away from the therapy suite for the duration of administration and the first hours post-dose (when external dose rate and exhalation/contamination risk are highest). Assign her the capsule uptake scan only if the capsule form eliminates volatilization risk; even then, keep her at distance and time-limited.
3. Use time-distance-shielding correctly: the therapy staff member uses distance and a shielded syringe/vial carrier; the pregnant technologist is not a substitute for shielding.
4. Contamination control: confirm the patient can swallow the liquid without spill, have emesis/saliva containment ready, and restrict the pregnant technologist from any cleanup.
5. Document the risk assessment, the reassignment rationale, and the fetal dose estimate (even if only bounding calculations) in her record.

If no non-pregnant competent staff can be arranged and the therapy is truly urgent, escalate to the RSO and radiation safety committee before proceeding - do not default to 'she does it with an apron.'

Judgment: This is a much lower-risk task than the therapy dose but still requires a formal decision, not an automatic yes.

Reasoning:

• A 7.4 MBq capsule removes the volatilization/aerosol risk that dominates liquid I-131 handling, and the activity is ~1.3% of the therapy dose. External dose from brief handling at distance is small.
• However, 'small' must be quantified against the fetal special limit (e.g., 0.5 mSv remainder-of-gestation). A rough bounding estimate using dose rate at 1 m, occupancy time, and inverse-square scaling should be documented. If the estimated fetal dose for the task is a negligible fraction of the remaining limit, the task may be permitted.
• Conditions: capsule form only (no liquid), short handling time, distance maintained, no patient contact beyond hand-off, and a fetal badge or ring dosimeter in place so actual dose is tracked.
• The decision belongs to the RSO with occupational health input, documented in writing.

Bottom line: Capsule uptake administration is plausibly acceptable after a documented dose estimate and with monitoring - but the technologist should not self-authorize it, and the answer is 'conditionally, if the numbers support it,' not 'yes because it's a capsule.'